会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING MULTIDRUG RESISTANT CANCER
    • 药物组合物和治疗多发性硬化性癌症的方法
    • WO2004064838A1
    • 2004-08-05
    • PCT/CA2004/000033
    • 2004-01-19
    • UNIVERSITY HEALTH NETWORKBERGER, Stuart, A.ZHANG, Yicheng
    • BERGER, Stuart, A.ZHANG, Yicheng
    • A61K31/4535
    • A61K45/06A61K31/4436A61K31/4535A61K31/704A61K2300/00
    • The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) a chemotherapeutic drug subject to multi-drug resistance by P-gp, such as doxorubicin or an analog thereof. The pharmaceutical composition is useful for treating cancer. The pharmaceutical composition is also useful for i) preventing or treating multi-drug resistance in a subject or ii) preventing a chemotherapeutic drug subject to multi-drug resistance by P-gp induced cardiac tissue damage in a subject, such as doxorubicin or an analog thereof. The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) a chemotherapeutic drug subject to multi-drug resistance by P-gp, such as doxorubicin or an analog thereof. The pharmaceutical composition is useful for treating cancer. The pharmaceutical composition is also useful for i) preventing or treating multi-drug resistance in a subject or ii) preventing a chemotherapeutic drug subject to multi-drug resistance by P-gp induced cardiac tissue damage in a subject, such as doxorubicin or an analog thereof.
    • 本发明涉及药物组合物,其包含i)酮替芬或其类似物,和ii)受P-gp多药耐药的化疗药物,例如多柔比星或其类似物。 该药物组合物可用于治疗癌症。 药物组合物还可用于i)预防或治疗受试者的多重耐药性,或ii)通过P-gp诱导的受试者的心脏组织损伤(例如多柔比星或类似物)预防受多药耐药性的化疗药物 它们。 本发明涉及药物组合物,其包含i)酮替芬或其类似物,和ii)受P-gp多药耐药的化疗药物,例如多柔比星或其类似物。 该药物组合物可用于治疗癌症。 药物组合物还可用于i)预防或治疗受试者的多重耐药性,或ii)通过P-gp诱导的受试者的心脏组织损伤(例如多柔比星或类似物)预防受多药耐药性的化疗药物 它们。
    • 3. 发明申请
    • COMPOSITIONS INCLUDING CALCIUM INFLUX BLOCKERS FOR INHIBITING CELL GROWTH
    • 组合物包括用于抑制细胞生长的钙通道阻断剂
    • WO1997025063A1
    • 1997-07-17
    • PCT/CA1997000019
    • 1997-01-13
    • THE WELLESLEY CENTRAL HOSPITALBERGER, Stuart, AlanGOMMERMAN, Jennifer, Lynn
    • THE WELLESLEY CENTRAL HOSPITAL
    • A61K45/06
    • A61K45/06
    • A general feature of the present invention is the induction of the death of stimulated cells by a Ca influx blocker. The invention, in its various aspects, includes administration of compositions that induce cell death including administration of a composition to a mammal, e.g., a human for therapeutic purposes; compositions, e.g., a composition having a Ca influx blocker and an agent which normally stimulates cells in which cell death is to be induced; kits of compositions, e.g., a kit having a Ca influx blocker and an agent which normally stimulates cells in which cell death is to be induced; use of such compositions or kits of compositions as anti-inflammatory agents and/or anti-proliferative agents; and use of a Ca influx blocker or use of Ca influx blocker and agent in the preparation of a medicament for use in inducing cell death. The invention includes a method for diagnosing the susceptibility of diseased animals to treatment with a Ca influx blocker or the combination of a Ca influx blocker and agent which normally stimulates cells in order that the treatment can induce cell death. The invention includes a method for screening potential compounds as Ca influx blockers.
    • 本发明的一般特征是通过Ca 2+流入阻断剂诱导刺激细胞的死亡。 本发明在其各个方面包括施用诱导细胞死亡的组合物,包括向哺乳动物(例如人)施用组合物用于治疗目的; 组合物,例如具有Ca 2+流入阻断剂的组合物和通常刺激其中诱导细胞死亡的细胞的试剂; 组合物试剂盒,例如具有Ca 2+流入阻断剂的试剂盒和通常刺激其中诱导细胞死亡的细胞的试剂; 使用这样的组合物或成套组合物作为抗炎剂和/或抗增殖剂; 以及使用Ca 2+流入阻断剂或使用Ca 2+流入阻断剂和药剂制备用于诱导细胞死亡的药物。 本发明包括用于诊断患病动物用Ca 2+流入阻断剂或Ca 2+流入阻断剂和通常刺激细胞的药剂的组合的敏感性的方法,以便该治疗可诱导细胞死亡 。 本发明包括用于筛选潜在化合物作为Ca 2+流入阻断剂的方法。